920036-28-8

Basic information

• Product Name: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-
• Synonyms: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-;6-Fluoro-3-Methyl-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 920036-28-8
• Molecular Formula: C7H6FN3
• Molecular Weight: 151.14
• Mol File: 920036-28-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(920036-28-8)
• EPA Substance Registry System: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(920036-28-8)

Safety Data

• Hazardous Substances Data: 920036-28-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYLis used as a potential candidate in drug development for its unique structure and properties that may contribute to the creation of new therapeutic agents. Its heterocyclic nature allows for versatile chemical modifications, which can be exploited to design drugs with specific pharmacological profiles.
Used in Research and Development:
As a research tool, 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYLaids in the study of biological processes and interactions. Its distinct chemical features make it valuable for probing molecular mechanisms and understanding the structure-activity relationships in drug discovery.
Used in Organic Synthesis:
1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-'s unique structure and properties also make it potentially useful in the synthesis of other organic compounds. Its reactivity and the presence of functional groups can be harnessed in various synthetic pathways to produce a range of chemical products with diverse applications.

Upstream product

• 920036-27-7 1-(2,6-difluoropyridin-3-yl)ethanone 
• 171178-50-0 2,6-difluoronicotinic acid 
• 937399-53-6 2,6-difluoro-N-methoxy-N-methyl-pyridine-3-carboxamide 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors

We identified a novel class of aryl-substituted triazine compounds as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) during a high-throughput screening campaign that evaluated more than 200000 compounds for antihuman immunodeficiency virus (HIV) activity using a cell-based full replication assay. Herein, we disclose the optimization of the antiviral activity in a cell-based assay system leading to the discovery of compound 27, which possessed excellent potency against wild-type HIV-1 (EC50 = 0.2 nM) as well as viruses bearing Y181C and K103N resistance mutations in the reverse transcriptase gene. The X-ray crystal structure of compound 27 complexed with wild-type reverse transcriptase confirmed the mode of action of this novel class of NNRTIs. Introduction of a chloro functional group in the pyrazole moiety dramatically improved hERG and CYP inhibition profiles, yielding highly promising leads for further development.

Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2- chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been shown to be a key component of highly active antiretroviral therapy (HAART). The use of NNRTIs has become part of standard combination antiviral therapies producing clinical outcomes with

HIV reverse transcriptase inhibitors

Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.